SEC Form SC 13G filed by Axsome Therapeutics Inc.

7/7/23 4:00:22 PM ET

$AXSM

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $AXSM alert in real time by email

SC 13G 1 tm2320767d1_sc13g.htm SC 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. ___)*

AXSOME THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, Par Value $0.0001

(Title of Class of Securities)

05464T104

(CUSIP Number)

June 28, 2023

(Date of Event Which Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

x Rule 13d-1(c)

¨ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 05464T104


1.	Names of Reporting Persons I.R.S. Identification No. of Above Persons (Entities Only) Fairmount Funds Management LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 2,344,980⁽¹⁾
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 2,344,980⁽¹⁾
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,344,980⁽¹⁾
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 5.0%⁽²⁾
12.	Type of Reporting Person (See Instructions) IA

(1) The shares reported herein for the Reporting Person represent 66,798 shares of the Issuer’s Common Stock held by Fairmount Healthcare Fund LP and 2,278,182 shares of the Issuer’s Common Stock held by Fairmount Healthcare Fund II LP (the “Funds”).

(2) Calculated based on 46,573,213 shares of the Issuer’s Common Stock outstanding as of June 28, 2023, as reported by the Issuer directly to the Reporting Person.

CUSIP No. 05464T104


1.	Names of Reporting Persons I.R.S. Identification No. of Above Persons (Entities Only) Peter Harwin
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 2,344,980⁽¹⁾
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 2,344,980⁽¹⁾
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,344,980⁽¹⁾
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 5.0%⁽²⁾
12.	Type of Reporting Person (See Instructions) HC, IN

(2) Calculated based on 46,573,213 shares of the Issuer’s Common Stock outstanding as of June 28, 2023, as reported by the Issuer directly to the Reporting Person.

CUSIP No. 05464T104


1.	Names of Reporting Persons I.R.S. Identification No. of Above Persons (Entities Only) Tomas Kiselak
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Slovak Republic
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 2,344,980⁽¹⁾
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 2,344,980⁽¹⁾
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,344,980⁽¹⁾
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 5.0%⁽²⁾
12.	Type of Reporting Person (See Instructions) HC, IN

(1) The shares reported herein for the Reporting Person represent 66,839 shares of the Issuer’s Common Stock held by Fairmount Healthcare Fund LP and 2,057,786 shares of the Issuer’s Common Stock held by Fairmount Healthcare Fund II LP (the “Funds”).

(2) Calculated based on 46,573,213 shares of the Issuer’s Common Stock outstanding as of June 28, 2023, as reported by the Issuer directly to the Reporting Person.

CUSIP No. 05464T104


1.	Names of Reporting Persons I.R.S. Identification No. of Above Persons (Entities Only) Fairmount Healthcare Fund II L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 2,278,182⁽¹⁾
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 2,278,182⁽¹⁾
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,278,182⁽¹⁾
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 4.9%⁽²⁾
12.	Type of Reporting Person (See Instructions) PN

(1) The shares reported herein for the Reporting Person represent 2,278,182 directly owned shares of the Issuer’s Common Stock.

(2) Calculated based on 46,573,213 shares of the Issuer’s Common Stock outstanding as of June 28, 2023, as reported by the Issuer directly to the Reporting Person.

CUSIP No. 05464T104


1.	Names of Reporting Persons I.R.S. Identification No. of Above Persons (Entities Only) Fairmount Healthcare Fund L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 66,798⁽¹⁾
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 66,798⁽¹⁾
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 66,798⁽¹⁾
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 0.1%⁽²⁾
12.	Type of Reporting Person (See Instructions) PN

(1) The shares reported herein for the Reporting Person represent 66,798 directly owned shares of the Issuer’s Common Stock.

(2) Calculated based on 46,573,213 shares of the Issuer’s Common Stock outstanding as of June 28, 2023, as reported by the Issuer directly to the Reporting Person.

Item 1.

(a)

Name of Issuer: Axsome Therapeutics, Inc.

(b)

Address of Issuer’s Principal Executive Offices: 22 Cortlandt Street, 16^th Floor, New York, NY 10007

Item 2.

(a)

Name of Person(s) Filing: This joint statement on Schedule 13G is being filed by Fairmount Funds Management LLC (“Fairmount”), Peter Harwin, Tomas Kiselak, Fairmount Healthcare Fund II L.P. (“Fund II”), and Fairmount Healthcare Fund L.P. (“Fund I”). Fairmount, Mr. Harwin, Mr. Kiselak, Fund II, and Fund I are collectively referred to herein as the “Reporting Persons.”

The Common Stock reported herein includes Common Stock beneficially owned directly by Fund I and Common Stock beneficially owned directly by Fund II. Fairmount Healthcare Fund GP LLC is the general partner of Fund I. Fairmount Healthcare Fund II GP LLC is the general partner of Fund II. The controlling persons of Fairmount are Mr. Harwin and Mr. Kiselak. Fairmount serves as investment adviser for Fund I and Fund II (together, the “Funds”) and may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the Issuer held by the Funds. The Funds have delegated to Fairmount the sole power to vote and the sole power to dispose of all securities held in the Funds’ portfolios, including the shares of the Issuer’s Common Stock reported herein. Because the Funds have divested voting and investment power over the reported securities and cannot revoke such delegation on less than 61 days’ notice, the Funds disclaim beneficial ownership of the securities for purposes of Section 13(d) of the Act and therefore disclaim any obligation to report ownership of the reported securities under Section 13(d) of the Act. As managing members of Fairmount, Mr. Harwin and Mr. Kiselak may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by Fairmount. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of the securities reported in this Schedule 13G Statement (the “Statement”) other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of the Statement shall not be deemed an admission that any of Fairmount, Mr. Harwin, or Mr. Kiselak is the beneficial owner of such securities for any other purpose.

(b)

Address of Principal Business Office: The principal business office of the Reporting Persons is c/o Fairmount Funds Management LLC, 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428.

(c)

Citizenship: Fairmount is a Delaware limited liability company. Mr. Harwin is a United States citizen. Mr. Kiselak is a Slovak Republic citizen. Fund II and Fund I are each a Delaware limited partnership.

(d)

Title of Class of Securities: Common stock, Par Value $0.0001 (“Common Stock”)

(e)

CUSIP Number: 05464T104

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

(a)	¨	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)	¨	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)	¨	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)	¨	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)	¨	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)	¨	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)	¨	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)	¨	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)	¨	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)	¨	A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

(k)	¨	Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: _______________.

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)            Amount Beneficially Owned:

As of the date of this filing, Fund I held 66,798 shares of Common Stock and Fund II held 2,278,182 shares of Common Stock.

(b)            Percent of Class:

See the response(s) to Item 11 on the attached cover page(s).

(i)             sole power to vote or to direct the vote:

See the response(s) to Item 5 on the attached cover page(s).

(ii)            shared power to vote or to direct the vote

See the response(s) to Item 6 on the attached cover page(s).

(iii)           sole power to dispose or to direct the disposition of

See the response(s) to Item 7 on the attached cover page(s).

(iv)           shared power to dispose or to direct the disposition of

See the response(s) to Item 8 on the attached cover page(s).

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable.

Item 8.

Identification and Classification of Members of the Group

Not applicable.

Item 9.

Notice of Dissolution of Group

Not applicable.

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: July 7, 2023

FAIRMOUNT FUNDS MANAGEMENT LLC

By:	/s/ Peter Harwin	/s/ Tomas Kiselak
Name:	Peter Harwin	Tomas Kiselak
Title:	Managing Member	Managing Member

PETER HARWIN

By:

/s/ Peter Harwin

	TOMAS KISELAK

	By:		/s/ Tomas Kiselak

FAIRMOUNT HEALTHCARE FUND II L.P. By: Fairmount Healthcare Fund II GP LLC

By:	/s/ Peter Harwin	/s/ Tomas Kiselak
Name:	Peter Harwin	Tomas Kiselak
Title:	Member	Member

FAIRMOUNT HEALTHCARE FUND L.P. By: Fairmount Healthcare Fund GP LLC

By:	/s/ Peter Harwin	/s/ Tomas Kiselak
Name:	Peter Harwin	Tomas Kiselak
Title:	Member	Member

Exhibit A

Joint Filing Agreement

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned and each other person executing this joint filing agreement (this “Agreement”) agree as follows:

(i) The undersigned and each other person executing this Agreement are individually eligible to use the Schedule 13G to which this Exhibit is attached and such Schedule 13G is filed on behalf of the undersigned and each other person executing this Agreement; and

(ii) The undersigned and each other person executing this Agreement are responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of the undersigned or any other person executing this Agreement is responsible for the completeness or accuracy of the information statement concerning any other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all of which, taken together, shall constitute one and the same instrument.

Dated: July 7, 2023

FAIRMOUNT FUNDS MANAGEMENT LLC

By:	/s/ Peter Harwin	/s/ Tomas Kiselak
Name:	Peter Harwin	Tomas Kiselak
Title:	Managing Member	Managing Member

PETER HARWIN

By:

/s/ Peter Harwin

	TOMAS KISELAK

	By:		/s/ Tomas Kiselak

FAIRMOUNT HEALTHCARE FUND II L.P. By: Fairmount Healthcare Fund II GP LLC

By:	/s/ Peter Harwin	/s/ Tomas Kiselak
Name:	Peter Harwin	Tomas Kiselak
Title:	Member	Member

FAIRMOUNT HEALTHCARE FUND L.P. By: Fairmount Healthcare Fund GP LLC

By:	/s/ Peter Harwin	/s/ Tomas Kiselak
Name:	Peter Harwin	Tomas Kiselak
Title:	Member	Member

Get the next $AXSM alert in real time by email

Date	Price Target	Rating	Analyst
4/7/2025	$200.00	Buy	Jefferies
2/11/2025	$176.00	Buy	Deutsche Bank
12/31/2024	$124.00 → $122.00	Outperform	Mizuho
9/3/2024	$140.00	Overweight	Wells Fargo
8/6/2024	$95.00 → $106.00	Neutral → Buy	BofA Securities
7/22/2024	$130.00	Buy	Needham
4/29/2024	$90.00 → $115.00	Equal-Weight → Overweight	Morgan Stanley
3/19/2024	$108.00	Outperform	Robert W. Baird

SEC Form SC 13G filed by Axsome Therapeutics Inc.

Chat with this insight

Recent Analyst Ratings for
$AXSM

$AXSM
Press Releases

Fastest customizable press release news feed in the world

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

Axsome Therapeutics to Participate in Upcoming Investor Conferences

$AXSM
SEC Filings

SEC Form 10-Q filed by Axsome Therapeutics Inc.

Axsome Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

SEC Form DEFA14A filed by Axsome Therapeutics Inc.

$AXSM
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for AUVELITY issued to AXSOME THERAPEUTICS, INC.

$AXSM
Leadership Updates

Live Leadership Updates

Axsome Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 7, 2023 deadline.

Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

$AXSM
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

$AXSM
Financials

Live finance-specific insights

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

$AXSM
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Jefferies initiated coverage on Axsome Therapeutics with a new price target

Deutsche Bank initiated coverage on Axsome Therapeutics with a new price target

Mizuho reiterated coverage on Axsome Therapeutics with a new price target

$AXSM
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Mahony Susan

SEC Form 4 filed by Director Jeffs Roger

SEC Form 4 filed by Director Saad Mark E

SEC Form SC 13G filed by Axsome Therapeutics Inc.

Chat with this insight

Recent Analyst Ratings for $AXSM

$AXSM Press Releases

Fastest customizable press release news feed in the world

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

Axsome Therapeutics to Participate in Upcoming Investor Conferences

$AXSM SEC Filings

SEC Form 10-Q filed by Axsome Therapeutics Inc.

Axsome Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

SEC Form DEFA14A filed by Axsome Therapeutics Inc.

$AXSM FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for AUVELITY issued to AXSOME THERAPEUTICS, INC.

$AXSM Leadership Updates

Live Leadership Updates

Axsome Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 7, 2023 deadline.

Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

$AXSM Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

$AXSM Financials

Live finance-specific insights

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

$AXSM Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Jefferies initiated coverage on Axsome Therapeutics with a new price target

Deutsche Bank initiated coverage on Axsome Therapeutics with a new price target

Mizuho reiterated coverage on Axsome Therapeutics with a new price target

$AXSM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Mahony Susan

SEC Form 4 filed by Director Jeffs Roger

SEC Form 4 filed by Director Saad Mark E

Recent Analyst Ratings for
$AXSM

$AXSM
Press Releases

$AXSM
SEC Filings

$AXSM
FDA approvals

$AXSM
Leadership Updates

$AXSM
Large Ownership Changes

$AXSM
Financials

$AXSM
Analyst Ratings

$AXSM
Insider Trading